Find Paid Research Studies in Tennessee

Browse Locations ... United States» ... Tennessee

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Typing Proficiency Following Carpal Tunnel Release

Condition: Carpal Tunnel Release
Intervention: Other: Typing assessment
Sponsors: Vanderbilt University; Vanderbilt University; Orthopaedic Research & Education Foundation (OREF)
Recruiting - verified May 2013
Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents

Conditions: Human Immunodeficiency Virus (HIV); Acquired Immunodeficiency Syndrome (AIDS)
Intervention: Other: Questionnaire
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Not yet recruiting - verified May 2013
Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Conditions: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Intervention: Drug: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Not yet recruiting - verified May 2013
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Conditions: Healthy Volunteers,; Chronic Renal Insufficiency
Interventions: Drug: LHW090; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Non-Myeloablative Conditioning and Bone Marrow Transplantation

Conditions: Sickle Cell Disease; Hemoglobinopathies
Interventions: Drug: Thymoglobulin; Drug: Fludarabine; Drug: Cyclophosphamide (CTX); Drug: Mesna; Drug: Sirolimus; Drug: Mycophenolate mofetil (MMF); Procedure: Bone marrow transplantation; Radiation: Total body irradiation
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Not yet recruiting - verified May 2013
Eat Well for Life: A Weight Loss Maintenance Study

Condition: Obesity
Interventions: Behavioral: Low-ED; Behavioral: Energy Balance
Sponsors: University of Tennessee; University of Tennessee; The Miriam Hospital
Recruiting - verified May 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013
The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
Care Transitions in Renal Disease Patients

Condition: Renal Disease
Intervention:
Sponsors: Fresenius Medical Care North America; Fresenius Medical Care North America; Amgen
Recruiting - verified April 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified April 2013
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream

Condition: Facial Angiofibroma
Intervention: Drug: Rapamune
Sponsors: Le Bonheur Children's Hospital; Le Bonheur Children's Hospital; Pfizer; University of Tennessee Health Science Center
Not yet recruiting - verified May 2013
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
Cardiogenesis Transmyocardial Revascularization Registry

Condition: Class IV Angina
Intervention:
Sponsors: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.; Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Recruiting - verified May 2013
Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial

Condition: Staphylococcus Aureus
Interventions: Drug: Mupirocin ointment; Drug: Mupirocin cream
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2013
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years.

Conditions: Meningococcal Vaccine; rLP2086; Hepatitis A Virus Vaccine; N Meningitidis Serogroup B; Meningitis
Interventions: Biological: rLP2086; Biological: rLP2086; Biological: rLP2086; Biological: Havrix (HAV); Biological: Saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Condition: HER2-mutant Non-Small Cell Lung Cancer
Interventions: Drug: neratinib; Drug: temsirolimus
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Recruiting - verified May 2013
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Conditions: Metastatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: ruxolitinib; Drug: gemcitabine; Drug: nab-paclitaxel; Drug: ruxolitinib
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified April 2013
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Biological: Margetuximab
Sponsors: MacroGenics; MacroGenics
Recruiting - verified May 2013
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: 5-fluorouracil; Drug: capecitabine; Radiation: radiation; Procedure: surgery; Drug: gemcitabine hydrochloride
Sponsors: Alliance for Clinical Oncology Trials; Alliance for Clinical Oncology Trials; National Cancer Institute (NCI)
Recruiting - verified April 2013
Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: ARN-810
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified April 2013
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Condition: Acute Myelogenous Leukemia
Intervention: Drug: MLN4924 and azacitidine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
SynapDx Autism Gene Expression Analysis Study (STORY)

Condition: Autism
Intervention:
Sponsors: SynapDx; SynapDx
Recruiting - verified May 2013
ADAM-Afatinib Diarrhea Assessment and Management

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: loperamide
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: rHIgM22 first dose; Drug: rHIgM22 second escalated dose; Drug: rHIgM22 third escalated dose; Drug: rHIgM22 fourth escalated dose; Drug: rHIgM22 fifth escalated dose; Drug: rHIgM22 sixth escalated dose
Sponsors: Acorda Therapeutics; Acorda Therapeutics; PRA International
Recruiting - verified May 2013
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified April 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Limited
Recruiting - verified April 2013
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2013
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Human Insulin NPH
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection

Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Human Regular U-500 Insulin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.

Conditions: Modified Release Oral Formulation; Left Ventricular Systolic Dysfunction; Chronic Heart Failure; History of Chronic Heart Failure; Left Ventricular Ejection Fraction; Pharmacokinetics; Echocardiogram
Interventions: Drug: Omecamtiv mecarbil; Drug: Omecamtiv mecarbil; Drug: Placebo; Drug: Omecamtiv Mecarbil; Drug: Omecamtiv Mecarbil
Sponsors: Amgen; Amgen; Cytokinetics
Recruiting - verified April 2013
Safety, Efficacy and Pharmacokinetics of ALD403

Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; German Breast Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified May 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: Dulaglutide; Drug: Glimepiride
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Study Evaluating the Effects of Avanafil on Semen Parameters

Condition: Erectile Dysfunction
Interventions: Drug: avanafil; Drug: Placebo
Sponsors: VIVUS, Inc.; VIVUS, Inc.
Recruiting - verified May 2013
STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
PK and PD Study of Calcitriol 3 Mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Condition: Plaque Psoriasis
Intervention: Drug: Calcitriol 3 mcg/g ointment
Sponsors: Galderma; Galderma
Recruiting - verified April 2013
Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659; Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Using MABp1 To Increase Overall Survival In Patients With Colorectal Cancer And Weight Loss

Conditions: Metastatic Colorectal Cancer; Cachexia; Weight Loss
Interventions: Drug: MABp1; Drug: Megestrol Acetate
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2013
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: Sarilumab SAR153191 (REGN88); Drug: Etanercept; Drug: Adalimumab
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Condition: Renal Impairment
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified April 2013
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: AVX 470; Drug: Placebo
Sponsors: Avaxia Biologics, Incorporated; Avaxia Biologics, Incorporated
Recruiting - verified May 2013
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Conditions: Inflammation; Crohn's Disease
Interventions: Drug: NNC0114-0006; Drug: NNC0114-0006
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Interventions: Drug: Tivozanib Hydrochloride; Drug: paclitaxel
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc
Recruiting - verified April 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer

Condition: Cancer
Interventions: Drug: Part 1 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 2 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 3 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 3 Cohort 3: 5-fluorouracil-based chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Rituximab
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Lymphoma
Intervention: Drug: CUDC-907
Sponsors: Curis, Inc.; Curis, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2013
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013
Early Diagnosis of Pulmonary Nodules

Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified April 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Conditions: Anemia; Myelodysplastic Syndromes (MDS); Chronic Myelomonocytic Leukemia (CMML); Low to Intermediate-1 MDS
Interventions: Drug: Sotatercept 0.1 mg/kg; Drug: Sotatercept 0.3 mg/kg; Drug: Sotatercept 0.5 mg/kg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Video Impact on Neulasta Education

Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Condition: Melanoma
Interventions: Drug: Talimogene laherparepvec plus ipilimumab; Drug: Ipilimumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (P07771/MK-3222-011)

Condition: Plaque Psoriasis
Interventions: Drug: MK-3222 200 mg; Drug: MK-3222 100 mg; Drug: MK-3222 Placebo; Drug: Etanercept Placebo; Drug: Etanercept 50 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Afatinib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Cisplatin; Radiation: Intensity Modulated Radiation Therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; National Comprehensive Cancer Network
Recruiting - verified May 2013
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: VX-135; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Condition: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Drug: Plecanatide; Drug: Placebo
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of LY2940680 in Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide; Drug: semaglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment

Condition: Dupuytren's Contracture
Intervention:
Sponsors: Auxilium Pharmaceuticals; Auxilium Pharmaceuticals
Recruiting - verified October 2012
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/insulin aspart; Drug: insulin degludec; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
NOLAN: Naproxen or Loratadine and Neulasta

Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Versartis Trial in Children to Assess Long-Acting Growth Hormone

Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
CARTO® 3 System and Real Time Intracardiac Ultrasound

Conditions: Atrial Fibrillation; Paroxysmal AF
Intervention: Device: Catheter Ablation
Sponsors: Biosense Webster, Inc.; Biosense Webster, Inc.
Recruiting - verified February 2013
Tdap Vaccine in Post-Partum Women

Conditions: Tetanus; Diphtheria; Pertussis
Intervention: Biological: Adacel® Tdap vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2013
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

Conditions: Stem Cell Transplant During Childhood; Allogeneic Bone Marrow Transplant During Childhood
Interventions: Other: Questionnaire; Other: Neurocognitive Evaluation
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo to MK-3102; Drug: Glipizide; Drug: Placebo to glipizide; Biological: Insulin
Sponsors: Merck; Merck
Recruiting - verified May 2013
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Conditions: Recurrent Childhood Acute B-lymphoblastic Leukemia; Recurrent Childhood B-lymphoblastic Lymphoma
Interventions: Drug: dexamethasone; Drug: vincristine sulfate; Biological: rituximab; Drug: clofarabine; Drug: cyclophosphamide; Drug: etoposide; Biological: aldesleukin; Drug: pegaspargase; Drug: methotrexate; Drug: mercaptopurine; Drug: cytarabine; Drug: mitoxantrone; Drug: teniposide; Drug: vinblastine; Biological: natural killer cell infusion; Other: laboratory biomarker analysis; Drug: therapeutic hydrocortisone; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Cookies for Kids' Cancer
Recruiting - verified April 2013
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer
Interventions: Drug: Rilotumumab; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2013
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: MK-3102 Placebo; Drug: Glimepiride; Drug: Glimepiride Placebo; Drug: Metformin; Drug: Insulin Glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
EverFlex Post Approval Study

Conditions: Peripheral Arterial Disease; Lower Extremity Arterial Disease
Intervention: Device: EverFlex™ Self-Expanding Peripheral Stent System
Sponsors: Covidien; Covidien
Recruiting - verified May 2013
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase III Study to Compare Efficacy and Safety of AFOLIA vs. Gonal-f® in Infertile Women 35 to 42 Years of Age Undergoing in Vitro Fertilization (IVF)

Condition: Infertility
Interventions: Drug: Gonal-f; Drug: AFOLIA
Sponsors: Finox AG; Finox AG
Not yet recruiting - verified April 2013
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Condition: Prostate Cancer
Interventions: Drug: AT13387 and abiraterone; Drug: AT13387 alone
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/Simvastatin FDC; Drug: Sitagliptin; Drug: Simvastatin; Drug: Placebo to sitagliptin; Drug: Placebo to simvastatin; Drug: Placebo to Sitagliptin/Simvastatin FDC; Drug: Metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified April 2013
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013
A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

Condition: Obsessive-Compulsive Disorder
Interventions: Drug: bitopertin; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
A Study of LY2228820 for Recurrent Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Condition: Gastric Cancer
Interventions: Drug: Onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified May 2013
Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013
Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients

Conditions: ST-elevation MI; Hypothermia
Interventions: Device: Velomedix APLS device; Other: No Hypothermia Treatment
Sponsors: Velomedix, Inc.; Velomedix, Inc.
Recruiting - verified May 2013
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)

Conditions: Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2013
Afatinib Expanded Access Program

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer

Conditions: Trismus; Head and Neck Cancer
Intervention: Device: Jaw Dynasplint System
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2013
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Condition: Pneumococcal Infections
Intervention: Biological: Prevnar 13 (PVC13)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2013
A Study of LY3023414 in Participants With Advanced Cancer

Conditions: Advanced Cancer; Metastatic Cancer; Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma
Interventions: Drug: LY3023414; Drug: Midazolam; Drug: Letrozole
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Condition: Gastric Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab emtansine; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Adult Congenital Heart Disease Registry (QuERI)

Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease
Intervention: Other: observational
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab-Pfizer (PF-05280586) x 3 courses; Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses; Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM2)

Condition: Asthma
Interventions: Drug: MK-1029 10 mg; Drug: MK-1029 30 mg; Drug: MK-1029 150 mg; Drug: Montelukast 10 mg; Drug: Placebo; Drug: MK-1029 1 mg or 3 mg; Drug: Montelukast 10 mg + MK-1029
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma

Condition: Glioblastoma
Interventions: Drug: onartuzumab; Drug: bevacizumab; Drug: onartuzumab placebo; Drug: bevacizumab placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis

Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
Osteonecrosis of the Jaw (ONJ) Case Registry

Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: Dulaglutide; Drug: Liraglutide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Conditions: Adult Primary Hepatocellular Carcinoma; Localized Resectable Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate; Other: placebo; Other: laboratory biomarker analysis
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Bayer
Recruiting - verified April 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Conditions: Advanced Melanoma; Metastatic Melanoma
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab; Biological: Tralokinumab; Other: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2013
A Study of IMC-TR1 in Patients With Advanced Solid Tumors

Conditions: Neoplasms; Tumor
Intervention: Biological: IMC-TR1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine; Drug: Lopinavir/ritonavir; Drug: Efavirenz; Drug: Raltegravir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2013
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor; Drug: Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

Conditions: Congestive Heart Failure; Left Ventricular (LV) Systolic Dysfunction
Intervention: Device: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
Sponsors: CardioKinetix, Inc; CardioKinetix, Inc
Recruiting - verified May 2013
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified April 2013
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Condition: Diabetic Nephropathy
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsors: Questcor Pharmaceuticals, Inc.; Questcor Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Eisenmenger Quality Enhancement Research Initiative

Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Conditions: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Intervention: Drug: Memantine Hydrochloride (HCl)
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified April 2013
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Condition: Gastric Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified May 2013
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Intervention: Drug: 120 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013
St. Jude Cancer Education for Children Program: The Feasibility of Teacher Delivery (Pilot Study)

Condition: Healthy
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Condition: Neoplasm Malignant
Interventions: Drug: SAR245408; Drug: SAR245409
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Recruiting - verified May 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine; Biological: IL-12 pDNA adjuvant; Biological: VSV HIV gag vaccine; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2013
Induction Chemotherapy w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin; Drug: ABVD Induction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Seattle Genetics, Inc.
Recruiting - verified April 2013
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: ACY-1215; Drug: lenalidomide; Drug: Dexamethasone
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated
Recruiting - verified May 2013
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Condition: Cancer
Interventions: Behavioral: survey, questionaire; Behavioral: survey, questionaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; St. Jude Children's Research Hospital; University of Colorado, Denver; Dana-Farber Cancer Institute; University of Chicago
Recruiting - verified April 2013
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1; Drug: Part 1, Cohort 2; Drug: Part 1, Cohort 3; Drug: Part 2, Cohort 1; Drug: Part 2, Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Condition: Advanced Metastatic Breast Cancer
Interventions: Drug: AZD2014; Drug: Fulvestrant
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Condition: Tuberculosis
Interventions: Drug: PA-824; Drug: Efavirenz (EFV); Drug: Lopinavir/Ritonavir (LPV/r); Drug: Rifampin (RIF)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

Condition: Parkinson's Disease
Intervention: Drug: nicotine transdermal patch
Sponsors: University of Vermont; James BOYD MD; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
Interventions: Drug: CC-223; Drug: Erlotinib; Drug: Oral azacitidine concurrent; Drug: oral azacitidine sequential
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913; Drug: Low dose ARA-C (LDAC); Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: Pf-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: PF-04449913; Drug: Low dose ARA-C (LDAC)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
Biomarker of Children With Familial Autoimmune History

Conditions: Autism; Children
Intervention:
Sponsors: Le Bonheur Children's Hospital; Le Bonheur Children's Hospital; University of Tennessee Health Science Center
Recruiting - verified May 2013
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: IMGN529
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified April 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Condition: Multiple Myeloma, Neoplasms
Intervention: Drug: Vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
A Study of RO4917523 in Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Long-term Safety and Tolerability of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Condition: Hypercholesterolemia
Interventions: Other: placebo; Drug: SAR236553 (REGN727)
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Conditions: Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013
Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids

Condition: Uterine Fibroids
Interventions: Device: MR-HIFU treatment; Device: Sham treatment
Sponsors: Philips Healthcare; Philips Healthcare
Recruiting - verified May 2013
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Condition: Prostate Cancer
Interventions: Drug: Se-methyl-seleno-L-cysteine; Dietary Supplement: selenium; Other: placebo; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2013
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
ATLAS - Anti-Tweak in Lupus Nephritis Patients

Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified April 2013
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: CC-486 plus Carboplatin; Drug: CC-486 plus ABI-007; Drug: CC-486
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2013
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: PCI-32765; Drug: Dexamethasone
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Condition: Central Nervous System
Intervention: Drug: perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Conditions: Atrial Fibrillation; Heart Failure
Interventions: Device: Reveal XT® Insertable Cardiac Monitor; Other: Heart Failure Risk Status Diagnostic
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified April 2013
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab; Biological: Pazopanib; Drug: Sunitinib; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified May 2013
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified May 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Condition: Spasticity
Interventions: Drug: Baclofen ER Capsules; Drug: Placebo GRS
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified April 2013
Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute
Recruiting - verified April 2013
Vest Prevention of Early Sudden Death Trial and VEST Registry

Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: University of California, San Francisco; University of California, San Francisco; Zoll Medical Corporation
Recruiting - verified April 2013
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma

Condition: Abdominal Neuroblastoma
Intervention: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Mayo Clinic
Recruiting - verified May 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified April 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified April 2013
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine [Kadcyla]; Drug: anti-cancer therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection

Condition: Craniopharyngioma
Interventions: Procedure: Radical Surgery or Limited Surgery; Radiation: Proton Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2013
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)

Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Blood Tests to Study Injury Severity and Outcome in Traumatic Brain Injury Patients

Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Elan Pharmaceuticals
Recruiting - verified April 2013
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified May 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384 AM3)

Condition: Bipolar 1 Disorder
Interventions: Drug: asenapine; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Condition: Primary Biliary Cirrhosis
Interventions: Drug: ustekinumab (double-blind); Drug: ustekinumab (double-blind); Drug: ustekinumab (open-label); Drug: ustekinumab (double-blind); Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adults With Myelofibrosis

Condition: Myelofibrosis
Interventions: Drug: GS-6624 at 700 mg; Drug: GS-6624 at 200 mg
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Drug: STX-100; Drug: Placebo
Sponsors: Stromedix, Inc.; Stromedix, Inc.
Recruiting - verified May 2013
Dystonia Coalition Projects

Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Conditions: Solid Tumor; Colorectal Cancer; Endometrial Cancer
Intervention: Drug: DS-7423
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2013
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age

Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination with azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility

Condition: Normal and Diseased Tissue and Body Fluids Samples
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
B0151003 Open-Label Extension Study

Condition: Crohn's Disease
Interventions: Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Condition: Cancer
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Condition: Carotid Stenosis
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Dysport® Adult Upper Limb Spasticity Extension Study

Condition: Nervous System Disorders
Intervention: Drug: Botulinum type A toxin (Dysport®)
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2013
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Condition: Graft Versus Host Disease (GVHD)
Interventions: Procedure: extracorporeal photopheresis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi; Sanofi
Recruiting - verified April 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Conditions: Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury
Interventions: Drug: IV Propranolol and Per Tube Clonidine; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; Vanderbilt Institute for Clinical and Translational Research (CTSA); Eastern Association for the Surgery of Trauma (EAST)
Recruiting - verified May 2013
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Conditions: Graft Versus Host Disease; Systemic Scleroderma
Interventions: Drug: imatinib mesylate; Biological: rituximab; Other: questionnaire administration; Procedure: biopsy; Other: cytology specimen collection procedure
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified April 2013
BAY81-8973 Pediatric Safety and Efficacy Trial

Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Therapeutics; BIND Therapeutics
Recruiting - verified April 2013
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors; Advanced Ovarian Cancer
Intervention: Drug: U3-1565
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Condition: Colitis, Ulcerative
Interventions: Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose
Sponsors: Pfizer; Pfizer; Athersys, Inc
Recruiting - verified May 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified April 2013
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: adult human mesenchymal stem cells
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified January 2013
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2013
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study in Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2940680
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

Condition: Stroke
Interventions: Drug: GM602; Drug: Matching Placebo (Bacteriostatic Saline) for GM602
Sponsors: Genervon Biopharmaceuticals, LLC; Genervon Biopharmaceuticals, LLC; University of California, Los Angeles; Huntington Hospital; Hoag Memorial Hospital Presbyterian; Columbia University; California Pacific Medical Center Research Institute; Erlanger Healthcare System; Sarasota Memorial Hospital; University of Louisville
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Condition: Neoplasms, Breast
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified May 2013
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
Post-Myocardial Infarction Remodeling Prevention Therapy

Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure
Interventions: Device: Single Site Pacing; Device: Dual Site Pacing
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula

Condition: Growth
Interventions: Other: Extensively hydrolyzed whey infant formula; Other: Extensively hydrolyzed casein infant formula
Sponsors: Nestlé; Nestlé
Recruiting - verified May 2013
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Conditions: Recurrent Thyroid Cancer; Stage I Follicular Thyroid Cancer; Stage I Papillary Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage III Follicular Thyroid Cancer; Stage III Papillary Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Conditions: Graft vs Host Disease; Cutaneous Sclerosis; Bronchiolitis Obliterans
Intervention:
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children

Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified April 2013
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

Condition: Cytomegalovirus Infections, Heart Transplantation
Intervention: Drug: valganciclovir [Valcyte]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified April 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2013
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: University of Miami; University of Miami; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
ZOSTAVAX® in Renal Transplant Patients

Condition: Herpes Zoster
Interventions: Drug: Placebo; Biological: ZOSTAVAX® (Zoster Vaccine Live)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

Condition: Vulvodynia
Intervention: Drug: Gabapentin extended-release
Sponsors: University of Tennessee; University of Tennessee; University of Tennessee Health Science Center
Recruiting - verified May 2013
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013
A Phase 1 Study in Participants With Advanced Cancer

Conditions: Advanced Cancer; Squamous Cell Carcinoma; Carcinoma, Squamous Cell of Head and Neck; Lung Squamous Cell Carcinoma Stage IV; Anal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: LY2606368
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsors: Sanofi; Sanofi
Recruiting - verified April 2013
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Conditions: Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium; Drug: cisplatin; Drug: cediranib maleate; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
INSIGHT Influenza Hospitalization Study (FLU 003)

Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified May 2013
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura

Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013
Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia

Condition: Exotropia
Interventions: Procedure: Bilateral lateral rectus recession (BLRrec); Procedure: Unilateral lateral rectus recession with medial rectus resection (R&R)
Sponsors: Jaeb Center for Health Research; Jaeb Center for Health Research; National Eye Institute (NEI)
Recruiting - verified May 2013
Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Condition: Human Papillomavirus
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Statins for Acutely Injured Lungs From Sepsis

Condition: Sepsis Induced ALI
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2013
Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer

Condition: Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified May 2013
nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Condition: Atrial Fibrillation
Intervention: Device: Numeris-AF Tethered Coagulation System with VisiTrax
Sponsors: nContact Surgical Inc.; nContact Surgical Inc.
Recruiting - verified April 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified April 2013
Strategic Timing of Antiretroviral Treatment

Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2013
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure

Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy; Radiation: Radiation Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
Progesterone for the Treatment of Traumatic Brain Injury

Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified March 2013
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified October 2012
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: cyclosporine ophthalmic emulsion; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2013
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013
Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials

Condition: Respiratory Distress Syndrome, Adult
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2013
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme; National Cancer Institute (NCI)
Recruiting - verified May 2013
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

Conditions: Severe Combined Immunodeficiency; Malignancy, Hematologic; Neuroblastoma; Neoplasm; Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Protocol For Collecting Long-Term Follow-Up Data On Recipients of Bone Marrow and Blood Stem Cell Transplant

Condition: Hematopoietic Stem Cell Transplantation
Intervention: Other: Data Collection
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions: Transthyretin Mutations; Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2013
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Condition: Rectal Cancer
Interventions: Drug: Cetuximab; Drug: 5-Fluorouracil; Radiation: External Beam Pelvis Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Bristol-Myers Squibb
Recruiting - verified April 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Induction Chemotherapy; Drug: Low-Risk Therapy; Drug: High-Risk Therapy; Drug: Intermediate-Risk Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; University of Florida
Recruiting - verified May 2013
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Conditions: Leukemia, Acute Lymphocytic (ALL); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Juvenile Myelomonocytic Leukemia (JMML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Hodgkin Lymphoma; Lymphoma, Non-Hodgkin (NHL); Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Systemic chemotherapy and antibodies
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2013
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study

Condition: Carotid Artery Disease
Intervention: Device: PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device
Sponsors: Covidien; Covidien
Recruiting - verified May 2013
Condition of Approval Study

Condition: Lumbar Spinal Stenosis
Intervention: Device: X-STOP PEEK
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Recruiting - verified April 2013
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents

Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease

Condition: Sickle Cell Disease
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Baylor College of Medicine
Recruiting - verified April 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression

Condition: Depression
Intervention: Drug: Bupropion
Sponsors: Meharry Medical College; Uma Rao; National Institute of Mental Health (NIMH)
Recruiting - verified April 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013

Find Paid Research Studies in Tennessee

Welcome to Paid Research Studies.